Findings demonstrate that high ALI values improve survival in unresectable hepatocellular carcinoma, suggesting ALI as a useful prognostic marker in therapy with Atezolizumab and Bevacizumab.
A high pretreatment ALI value was associated with improved survival and disease control in u-HCC patients receiving Atez/Bev, underscoring its potential utility as a prognostic marker for clinical management and further studies.
No takes yet. Share an insight, caveat, or question.
Nguyễn et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: